Trifecta Capital Advisors LLC decreased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 33.1% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 405 shares of the company’s stock after selling 200 shares during the quarter. Trifecta Capital Advisors LLC’s holdings in IDEXX Laboratories were worth $217,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of IDXX. Red Spruce Capital LLC increased its position in IDEXX Laboratories by 1.1% during the 2nd quarter. Red Spruce Capital LLC now owns 1,701 shares of the company’s stock valued at $912,000 after buying an additional 19 shares in the last quarter. Rise Advisors LLC increased its position in IDEXX Laboratories by 3.9% during the 2nd quarter. Rise Advisors LLC now owns 562 shares of the company’s stock valued at $301,000 after buying an additional 21 shares in the last quarter. Sage Mountain Advisors LLC increased its position in IDEXX Laboratories by 3.8% during the 1st quarter. Sage Mountain Advisors LLC now owns 635 shares of the company’s stock valued at $267,000 after buying an additional 23 shares in the last quarter. Great Lakes Advisors LLC increased its position in IDEXX Laboratories by 0.9% during the 1st quarter. Great Lakes Advisors LLC now owns 2,567 shares of the company’s stock valued at $1,078,000 after buying an additional 23 shares in the last quarter. Finally, PDS Planning Inc increased its position in IDEXX Laboratories by 3.9% during the 1st quarter. PDS Planning Inc now owns 641 shares of the company’s stock valued at $269,000 after buying an additional 24 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.
Analyst Ratings Changes
Several brokerages recently issued reports on IDXX. BTIG Research upped their target price on IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a research report on Tuesday, August 5th. Stifel Nicolaus set a $640.00 price target on IDEXX Laboratories in a research note on Monday, August 4th. JPMorgan Chase & Co. boosted their price target on IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a research note on Monday, August 4th. Weiss Ratings reiterated a “buy (b-)” rating on shares of IDEXX Laboratories in a research note on Wednesday. Finally, UBS Group began coverage on IDEXX Laboratories in a research note on Wednesday, October 1st. They set a “neutral” rating and a $720.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $656.50.
Insider Transactions at IDEXX Laboratories
In other news, EVP Michael G. Erickson sold 406 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total value of $263,883.76. Following the sale, the executive vice president owned 11,287 shares in the company, valued at $7,336,098.52. This represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director M Anne Szostak sold 2,187 shares of the company’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $647.33, for a total value of $1,415,710.71. Following the completion of the sale, the director owned 262 shares in the company, valued at $169,600.46. The trade was a 89.30% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 54,057 shares of company stock valued at $34,293,468. 0.98% of the stock is owned by insiders.
IDEXX Laboratories Stock Up 0.4%
Shares of IDXX opened at $629.91 on Thursday. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $688.12. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $50.40 billion, a price-to-earnings ratio of 52.45, a PEG ratio of 4.06 and a beta of 1.58. The stock’s 50-day moving average price is $637.99 and its 200-day moving average price is $539.07.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the prior year, the business earned $2.44 earnings per share. The company’s revenue was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Featured Stories
- Five stocks we like better than IDEXX Laboratories
- Investing in Travel Stocks Benefits
- Lowe’s vs. Home Depot: Which Benefits More From Lower Rates?
- What is a support level?
- These 5 Beaten-Down Tech Stocks Could Catch Fire Next
- How to Calculate Stock Profit
- Falcon Flex Drives Growth as CrowdStrike Bets on AI Security
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.